Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, specifically as alpha-tocopherol, has been studied for its potential role in supporting or treating age-related macular degeneration (AMD), largely based on its antioxidant properties. The primary scientific basis comes from large randomized controlled trials, most notably the Age-Related Eye Disease Study (AREDS) and its follow-up AREDS2. In the original AREDS trial, a combination supplement containing vitamin E (400 IU daily), vitamin C, beta-carotene, zinc, and copper was shown to reduce the risk of progression to advanced AMD by about 25% in individuals at high risk. However, vitamin E was not tested alone, and subsequent analyses suggest its effect may be modest and dependent on the combination with other antioxidants and minerals. Further, the AREDS2 study replaced beta-carotene with lutein and zeaxanthin but continued to include vitamin E. The results confirmed a modest benefit in reducing the risk of advanced AMD progression, but again, the individual contribution of vitamin E remains unclear. No substantial evidence supports vitamin E supplementation alone in preventing the onset or progression of AMD. Most major ophthalmology organizations recommend antioxidant vitamin and mineral combinations similar to the AREDS/AREDS2 formulas for certain patients with intermediate or advanced AMD, not for the general population. Thus, while vitamin E is part of the recommended regimen, the evidence for its standalone efficacy is limited, and its use is scientifically validated only as part of a combination supplement.

More about Vitamin E (alpha-tocopheryl hydrochloride)
More about Macular Degeneration

Other ingredients used for Macular Degeneration

Other health conditions supported by Vitamin E (alpha-tocopheryl hydrochloride)

Products containing Vitamin E (alpha-tocopheryl hydrochloride)